Freenome
279 East Grand Avenue
5th Floor
South San Francisco
California
94080
United States
Tel: (650) 446-6630
Website: http://www.freenome.com/
Email: careers@freenome.com
About Freenome
Mission
Freenome is a high growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease.
Approach
To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas.
Funding
We have raised more than $1.1B from leading investors including Andreessen Horowitz, Bain Capital, GV, Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Novartis, Verily, and more.
Freenomers
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.
What is Freenome? First and foremost, Freenome is a team. A cross-collaborative, mission-driven team developing next-generation blood tests for early cancer detection, so that we can find cancer when it’s most treatable.
40 articles with Freenome
-
Freenome Adds Several Community Partners to Clinical Study for the Detection of Cancer, Expanding Reach and Representation
11/1/2022
Freenome announced 50 hospitals and community oncology practices across the United States have joined as clinical partners for its Vallania Study.
-
Freenome Continues Growth, Adds Three New Leaders
6/2/2022
Freenome, a privately held biotech company, announced three executives have joined the company to support its continued growth.
-
FREENOME AND MERCK KGAA, DARMSTADT, GERMANY TO PRESENT DATA ON COMBINATION OF MULTIOMICS PROFILING AND COMPUTATIONAL MODELING AT AACR ANNUAL MEETING
4/13/2022
Freenome announced its co-authorship of a study with Merck KGaA, Darmstadt Germany, a leading science and technology company.
-
Freenome Presents Research That Highlights The Significance Of Detecting Adenomas In Any Test That Screens For Colorectal Cancer
4/11/2022
Freenome, a privately held biotech company, will present research at the American Association for Cancer Research Annual Meeting that measures the clinical impact of detecting precancerous adenomas for tests that screen for colorectal cancer, including multi-cancer early detection tests.
-
BioSpace Movers & Shakers, April 8
4/8/2022
Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week. -
FREENOME LAUNCHES THE VALLANIA STUDY FOR THE EARLY DETECTION OF MULTIPLE CANCERS
2/28/2022
Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study for the refinement and further development of its multiomics platform to detect multiple cancers.
-
Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer
1/11/2022
Freenome, a privately held biotech company, announced that Roche has made an investment of $290 million, bringing Freenome's total funding to more than $1.1 billion since the company was founded in 2014.
-
Roche’s investment is aimed at supporting the development of Freenome’s colorectal cancer detection technology.
-
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
12/7/2021
Freenome, a privately held biotech company, announced a Series D funding of $300 million. This brings the company's total financing to over $800 million since the company was founded in 2014.
-
Freenome Partners with Siemens Healthineers for Breast Cancer Research
12/1/2021
Freenome, a privately held biotech company, announced a partnership with Siemens Healthineers to collaborate in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies.
-
Freenome Shows Continued Leadership in Colorectal Cancer Research
10/25/2021
Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology annual meeting that underscores their commitment to improving colorectal cancer screening.
-
The new CEO of Freenome has a talent for “making his own weather.” That’s a phrase he heard often growing up in Rapid City, South Dakota and, when applied to his life and career, comes down to assessing himself accurately and looking for opportunities to contribute.
-
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
-
Freenome Presents Data Demonstrating the Importance of Clinical Test Performance and Screening Adherence on Colorectal Cancer Outcomes
5/21/2021
Freenome presents findings from the CRC-MAPS™ model at the Digestive Disease Week (DDW) 2021 Annual Meeting
-
Freenome Presents Data Revealing Signatures of Immune Checkpoint Inhibitor Treatment Response Found to Be Common Across Kidney, Melanoma, and Lung Cancers
4/10/2021
Freenome demonstrates potential for patient stratification and monitoring using its multiomics platform at the American Association for Cancer Research (AACR) Annual Meeting
-
Freenome’s Multiomics Blood Test Shows Promising Results in Detecting Colorectal Advanced Adenomas in a Prospective, Multi-Center Clinical Study
1/12/2021
New results from the AI-EMERGE® study show Freenome’s multiomics blood test can detect colorectal advanced adenomas at 41% sensitivity and 90% specificity, which is comparable to or better than currently available non-invasive tests for colorectal cancer screening. This data, to be presented at ASCO-GI, build on previously reported data from a separate cohort that showed Freenome’s multiomics blood test can detect early-stage colorectal cancer
-
PREEMPT CRC™ Trial for Blood-Based Test to Detect Colon Cancer Has Expanded to Enroll Patients From Anywhere in the Continental U.S. During COVID-19 Pandemic
8/26/2020
COVID-19 pandemic has caused significant decline in colonoscopies and underscores the value of less invasive screening options for colorectal cancer (CRC)
-
Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
8/26/2020
Proceeds will accelerate ongoing FDA registrational study of company’s first blood test for colorectal cancer screening and advance product pipeline
-
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing.
-
Freenome Announces Initiation of the PREEMPT CRC Clinical Trial, a Registrational Study for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test
5/26/2020
Freenome , a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced several new developments: initiating its PREEMPT CRC clinical trial; adding Gary Reedy, CEO of the American